Immunotech Biopharm Ltd. announce that the Company has completed the first patient enrolment for its Phase II clinical trial for CAR-T-19 injection ("CAR-T-19 Injection") in the PRC, which marked a key milestone of the Group's development in its product pipeline. CAR-T-19 Injection is indicated for the treatment of pediatric and young adult patients up to and including the age of 25 with relapsed/refractory B cell acute lymphoblastic leukaemia ("B-ALL"). Based on the progress of clinical trial for CAR-T-19 Injection, it is expected that the target patient enrolment would complete by the end of 2025 and the preliminary analysis and results would be published in the first half of 2026.